EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly iD, Mahmoud Obeidat, Rita Nagy, Péter Hegyi iD, Brigitta Teutsch, Eszter Tuboly, Miklós Garami iD

Pediatric Blood & Cancer · 2026-07 · 73 (7)

DOI: 10.1002/1545-5017.70318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 20.04.2026. Verfasst von Janka Kovács und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre For Translational Medicine, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Drug Monitoring, Benzimidazoles, Neurofibroma, Plexiform. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects. Study design In this single‐center pilot study, selumetinib plasma concentrations were measured in 22 pediatric NF1 patients receiving treatment for PN. Serial blood sampling was performed at steady‐state, and concentrations were quantified using liquid chromatography–tandem mass spectrometry. Noncompartmental modeling was used to estimate pharmacokinetic parameters, including the area under the concentration–time curve (AUC). Clinical outcomes, imaging findings, and treatment‐related adverse events were recorded.

Results

Among 24 children included for clinical evaluation, one demonstrated PN regression, 20 had stable disease, and three showed slow progression. Fourteen patients experienced adverse effects, most commonly cutaneous toxicity and creatine‐kinase elevation. AUC values were analyzed in 18 patients with stable diseases. Those with adverse events exhibited higher dose‐normalized AUCs (4374–13,923 nmol*h/L) than those without toxicity (2961–6011 nmol*h/L). One asymptomatic patient had an unusually high AUC (22,512 nmol*h/L), influencing group distribution. No clear associations were observed between AUC and demographic or routine clinical variables.

Conclusion

Higher selumetinib exposure appears to be associated with treatment‐related adverse effects in pediatric NF1 patients. These findings support the potential role of TDM in optimizing selumetinib dosing and provide a preliminary therapeutic AUC range for individualized treatment strategies. Larger multicenter studies are needed to validate these results and refine exposure‐guided dosing approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1Drug MonitoringBenzimidazolesNeurofibroma, PlexiformPrecision MedicineHumansFemalePilot ProjectsChildMaleChild, PreschoolAdolescentFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

neurofibromatosis type 1pharmacokineticsplexiform neurofibromaselumetinibtherapeutic drug monitoring

Substanzen

BenzimidazolesAZD 6244

Autor:innen und Institutionen

  • Centre For Translational Medicine, Semmelweis University, Budapest, Hungary.
  • Pediatric Center, MTA Center of Excellence, Semmelweis University, Budapest, Hungary.
  • Department of Laboratory Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
  • Heim Pál National Pediatric Institute, Budapest, Hungary.
  • Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
  • Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.

ORCID-Profile: Balázs Gellért Karvaly, Péter Hegyi, Miklós Garami

Zitieren

APA

Kovács, J., Köllő, Z., Karvaly, B. G., Obeidat, M., Nagy, R., Hegyi, P., Teutsch, B., Tuboly, E., & Garami, M. (2026). Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study. Pediatric Blood & Cancer, 73(7). https://doi.org/10.1002/1545-5017.70318

Vancouver

Kovács J, Köllő Z, Karvaly BG, Obeidat M, Nagy R, Hegyi P, et al. Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study. Pediatric Blood & Cancer. 2026;73(7). doi:10.1002/1545-5017.70318

BibTeX
@article{Kovcs2026,
  author = {Kovács, Janka and Köllő, Zoltán and Karvaly, Balázs Gellért and Obeidat, Mahmoud and Nagy, Rita and Hegyi, Péter and Teutsch, Brigitta and Tuboly, Eszter and Garami, Miklós},
  title = {Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {7},
  doi = {10.1002/1545-5017.70318}
}
Kostenlos starten →